Table 2.
Univariate analysis of factors predicting recurrence-free and overall survival
| Variable | Median RFS (months) | Recurrence-free survival | Median OS (months) |
Overall survival | |||
|---|---|---|---|---|---|---|---|
| HR | P (95% CI) | HR | P (95% CI) | ||||
| Overall | 15.0 | 17.0 | |||||
| Sex | |||||||
| Female | 13.0 | 1 | 0.336 (0.853–1.593) | 16.9 | 1 | 0.270 (0.872–1.634) | |
| Male | 15.0 | 1.166 | 17.4 | 1.193 | |||
| Age (year) | |||||||
| Less than 61 | 16.0 | 1 | 0.208 (0.899–1.630) | 19.2 | 1 | 0.032 (1.028–1.876) | |
| 61 or greater | 13.0 | 1.211 | 16.3 | 1.388 | |||
| Tumor site | |||||||
| Intrahepatic | 12.5 | 1 | 0.449 (0.664–1.199) | 16.0 | 1 | 0.560 (0.680–1.232) | |
| Extrahepatic | 16.0 | 0.892 | 18.5 | 0.915 | |||
| Histology type | |||||||
| Papillary | 16.0 | 1 | 0.253 (0.884–1.599) | 17.6 | 1 | 0.759 (0.779–1.409) | |
| Others | 13.0 | 1.189 | 16.3 | 1.047 | |||
| Primary tumor (T) | |||||||
| I, II | 18.0 | 1 | < 0.001 (1.956–3.771) | 22.0 | 1 | < 0.001 (1.907–3.629) | |
| III, IV | 9.0 | 2.716 | 11.0 | 2.630 | |||
| Reginal lymph nodes (N) metastasis | |||||||
| No | 17.0 | 1 | 0.001 (1.265–2.362) | 20.0 | 1 | < 0.001 (1.442–2.704) | |
| Yes | 10.5 | 1.729 | 13.0 | 1.975 | |||
| Distant metastasis (M) | |||||||
| No | 15.0 | 1 | 0.762 (0.432–3.150) | 17.0 | 1 | 0.519 (0.513–3.751) | |
| Yes | 12.0 | 1.166 | 13.5 | 1.387 | |||
| TNM stage | |||||||
| I, II | 18.0 | 1 | < 0.001 (1.576–2.986) | 21.6 | 1 | < 0.001 (1.711–3.255) | |
| III, IV | 10.0 | 2.169 | 12.8 | 2.360 | |||
| Post-operative CMT | |||||||
| No | 15.0 | 1 | 0.933 (0.727–1.340) | 16.9 | 1 | 0.556 (0.671–1.239) | |
| Yes | 15.0 | 0.987 | 19.0 | 0.912 | |||
| CD44 | |||||||
| Low | 18.0 | 1 | 0.007 (1.129–2.170) | 22.0 | 1 | 0.001 (1.250–2.399) | |
| High | 13.0 | 1.565 | 16.1 | 1.732 | |||
| CD44v6 | |||||||
| Neg. | 17.0 | 1 | 0.001 (1.234–2.311) | 19.2 | 1 | 0.006 (1.128–2.081) | |
| Pos. | 11.0 | 1.689 | 12.8 | 1.532 | |||
| CD44v8-10 | |||||||
| Neg. | 16.0 | 1 | 0.007 (1.125–2.072) | 20.0 | 1 | < 0.001 (1.271–2.352) | |
| Pos. | 13.0 | 1.527 | 14.1 | 1.729 | |||
| CD133 | |||||||
| Neg. | 16.0 | 1 | 0.103 (0.949–1.765) | 18.1 | 1 | 0.083 (0.965–1.794) | |
| Pos. | 12.5 | 1.295 | 16.1 | 1.316 | |||
| EpCAM | |||||||
| Low | 14.0 | 1 | 0.135 (0.594–1.073) | 16.3 | 1 | 0.261 (0.629–1.134) | |
| High | 16.0 | 0.798 | 18.6 | 0.844 | |||
| ALDH1A1 | |||||||
| Low | 11.0 | 1 | 0.075 (0.569–1.028) | 16.0 | 1 | 0.022 (0.525–0.950) | |
| High | 17.0 | 0.765 | 19.9 | 0.706 | |||
TNM primary tumor-node-metastasis, post-operative, CMT post-operative chemotherapeutic treatment, HR hazard ratio, 95% CI 95% confidence interval, CD44 cluster of differentiation 44, CD44v CD44 variant, CD133 cluster of differentiation 133, EpCAM epithelial cell adhesion molecules, ALDH1A1 aldehyde dehydrogenase 1A1, TNM primary tumor-node-metastasis, Neg negative expression, Pos positive expression